Although the possibility of inducing p53-mediated DNA damage by genome editing with CRISPR/Cas9 has been discussed [39], we believe that this effect of the sgRNA on the growth of T cells does not pose a risk of cancer occurrence or progression. This evidence concerns the gene TP53 and cancer.